anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
TMC207 is being investigated for the treatment of MDR-TB infection. This is a Phase I, open-label, randomized crossover trial in healthy volunteers to investigate the potential interaction between steady-state lopinavir/ritonavir (LPV/rtv) 400/100 mg twice daily and a single dose of 400 mg TMC207. The trial population will consist of 16 healthy volunteers. During 2 sessions, each participant will receive 2 treatments (Treatments A and B) in a randomized order. This means it will be decided by chance if subjects will receive first treatment A, then B or first treatment B, then A.

In Treatment A, participants will receive a single dose of TMC207 400 mg on Day 1. In Treatment B, participants will receive LPV/rtv 400/100 mg twice daily on Days 1 to 24, while on Day 11 a single dose of TMC207 400 mg will be co-administered. The two single doses of TMC207 will be administered 4 weeks apart. Consequently, Treatment B should start 4 days after completion of Treatment A, and Treatment A should start 14 days after completion of Treatment B (counting from the day the last PK sample has been collected). Pharmacokinetic profiles over 336 hours will be determined for TMC207 and its N-monodesmethyl metabolite (M2) after administration of TMC207 400 mg alone (Day 1 of Treatment A), and in combination with steady-state LPV/rtv (Day 11 of Treatment B). Morning predose concentrations of lopinavir and ritonavir will be determined at several time points. Safety and tolerability will be evaluated throughout the trial. Day 1 of Treatment A and on Day 11 of Treatment B, 400 mg TMC207 (1 tablet) will be taken orally in the morning within 10 mins. after completion of a meal. Days 1 to 24 of Treatment B, 2 tablets of Lopinavir/Ritonavir (LPV/rtv = 400 mg lopinavir and 100 mg ritonavir) will be taken in the morning and evening. When LPV/rtv is administered alone, it can be taken with or without food. When co-administered simultaneously with TMC207, LPV/rtv intake will be within 10 mins. after completion of a meal.
This group will receive Jacobson's Progressive Muscle Relaxation Technique. Jacobson's relaxation technique is a type of therapy that focuses on tightening and relaxing specific 14 muscle groups in sequence. It's also known as progressive relaxation therapy. By concentrating on specific areas and tensing and then relaxing them, you can become more aware of your body and physical sensations, The sessions will consist of 30 minutes in a day, 3 days per week for 8 weeks. (total no. of sessions=24).
A total of 14 diet studies (each with two meals) were completed in three men and four women. All subjects completed two diet studies in which two meals were served 195 minutes apart. On one study day, two high GI (\> 75) meals were given, and on the other study day, two low GI (\< 30) meals were given. The low GI and high GI meals were matched for amount of carbohydrates, protein, and fat based on a weight-maintaining diet for each subject. The order of the study treatment (high or low GI) was randomized. Subjects were not informed as the GI of any meal.
Sprayable agents for application to the skin consist of one or more liquid carriers which volatilise on the skin and one or more finely divided amorphous solids suspended in the liq. phase. The content of liquid carriers is higher than the solids content, and the solids remain in suspension during the spraying process until the site of application is reached. The ratio of liquid carrier to solid is pref. 3-10:1. Pref. liquid carriers are ethanol, n-propanol, isopropanol and water or their mixtures; the suspended amorphous solids may be e.g. talc, starch, starch derivatives, metal stearates, silica derivatives, zinc oxide, titanium dioxide, pigments, dyes and/or pharmaceuticals. Retention of the solid in suspension until the spray reaches the skin avoids the inhalation of dust. After volatilisation of the liquid carrier, the solid adheres well to the skin.
Participants who refuse randomization to receive posture and movement training may continue participation in an observational group. These participants complete the same baseline and follow-up testing but proceed with their treatment-of-choice during the 3-week intervention period.
The present invention relates to a novel gene, Di12, that is differentially expressed as a 1.35 kb RNA in breast cancer tissues and cell lines, and in several normal tissues. The full length cDNA encodes a protein of 339 amino acids. Antibodies to the gene product were developed to investigate the expression of Di12 in breast cancer cell-lines and tumors. The Di12 protein was found in tissue sections of infiltrating ductal carcinomas (IDCs), but not in benign or normal breast specimens. Di12 was also present in IDC-breast cancer patient sera, and its expression level increased markedly if IDC was accompanied by lymph node or distal metastases. As IDC constitutes 70 % of breast cancers seen clinically, the level of Di12 expression is useful for diseases diagnosis predicting disease progression and monitoring a therapeutic treatment.
Patients and parents will use MigraineManager to complete assessment measures at baseline and post-treatment (i.e., 2 months after baseline). Answers to these measures will determine what interventions each participant will receive. Data obtained in this phase will be used to make final modifications to MigraineManager for large scale testing.
The mycotoxin deoxynivalenol (DON) is frequently present in cereals at low levels, resulting in its occurrence in food and feed. DON has been proven to alter the immune response and induce inflammation in all species, with pigs exhibiting heightened sensitivity and exposure. However, no study has yet evaluated the effects of exposure to DON at the recommended levels in pig feed. In two separate trials, piglets were subjected to control feed or feed contaminated with a low level of purified DON (0.83 mg/kg feed in trial 1 and 0.85 mg/kg feed in trial 2) for either three weeks (trial 1) or two weeks (trial 2). Additionally, a group of animals exposed to 2.85 mg/kg feed of DON was included as a positive control in Trial 1. The impact of DON on porcine tissues (intestine, liver, and spleen) was evaluated through histological and qPCR analyses of immune-related genes. Additionally, biochemical analyses and acute-phase proteins were examined in plasma samples. Lesions were identified in the intestine (jejunum and ileum), the liver, and the spleen of pigs receiving diets contaminated with low and high concentrations of DON. The low level of DON also resulted in impaired expression of genes associated with intestinal barrier integrity, intestinal immune responses, and liver function. In conclusion, the results of the two trials demonstrate the impact of DON exposure even at doses below the recommended level of 0.9 mg/kg feed set by the European Union. This suggests that the current recommended level should be reconsidered to ensure the optimal health and well-being of pigs.
In a 10-week double-blind placebo controlled outpatient clinical trial, the safety and efficacy ofpregabalin will be tested in 50 outpatients with Alcohol Use Disorder.Participants will be randomly allocated (1:1) to receive pregabalin or an identical-appearing, inert placebo. All study medication (placebo and pregabalin) will be over-capsulated with riboflavin to assess compliance. Pregabalin will be administered in 75 mg and 100 capsules; placebo capsules will appear identical to the pregabalin capsules. Participants in both study arms will receive the same number of capsules. Pregabalin will be titrated over a 3-week period to the FDA maximum (600 mg per day) or the maximum tolerated dose.

Study visits will occur daily for the first 4 days of the study period, then approximately every other day for the remainder of week 1, for a total of 5 study visits (study days 1,2,3,4, and 5 or 7). During the second week, study visits will continue every other day for a total of 3 study visits (study days 8,10, and 12). During the remainder of the 8-week medication study period, study visits will occur twice weekly. There will be two visits during a post-study taper week (week 9) and a follow-up visit during week 10. One visit per week will be with the research psychiatrist. All participants will have a weekly supportive behavioral treatment session with the research psychiatrist using a manual designed for pharmacotherapy trials in subjects with alcohol use disorders
PURPOSE:To obtain an incense capable of making people enjoy the incense and then taking pleasure in looking at color of changing ash, by blending a raw material for an incense or stick of incense with inorganic pigment, kneading the blend with water or warm water, molding, drying and burning incense. CONSTITUTION:A raw material for an incense or stick of incense is blended with one or plural colored or white inorganic pigments to give a mixed material, which is kneaded with water or arm water into a mixed state, molded and then dried to give the aimed substance. The blending ratio is 1-70pts.wt. pigment and 99-30pts.wt. incense or stick of incense and 100pts.wt. of the blend is kneaded with about 70pts.wt. water or warm water. Oxide of Ti, Ni, Sb, Cr or Co is used as the pigment and the kneaded material can be molded into a shape such as conic, spiral, heart-shaped, triangular, circular or animal form. Cinders of molded incense change from yellow to pink, blue, green and white and people can take pleasure in looking at change of color.
The present invention relates to a cosmetic composition containing hyalucollagen (hyaluronic acid, marine collagen, and a Dioscorea japonica Thunb. root extract) as an active ingredient. Hyalucollagen, a novel mixed raw ingredient, is produced by bonding hyaluronic acid and marine collagen together, and then mixing the Dioscorea japonica Thunb. root extract therewith. By mixing the hyalucollagen with a cosmetic product, a skin moisturizing function is more enhanced than an existing cosmetic product or the case when adding hyaluronic acid, marine collagen, and the Dioscorea japonica Thunb. root extract respectively. The hyalucollagen also reduces fine wrinkles and keeps skin sleek and elastic while increasing an antioxidant function. In addition, the cosmetic composition is a novel invention ensuring more improved applicability than an existing cosmetic product.
Retrolaminar block will be applied under ultrasound guidance. Pain measurements were evaluated 24 hours after surgery. Pain measurement will be evaluated according to the VAS scale.
BACKGROUND: Since differentiating malignant ascites from benign ascites has always been a clinical difficult, recognition of novel biomarkers in malignant ascites of hepatocellular carcinoma (HCC) patients could be helpful for establishing a diagnosis for HCC patients with ascitic fluids.
METHODS: Thirty-five HCC patients with malignant ascites and chronic liver diseases patients with benign ascites were enrolled. Serum and ascites specimens were collected to determine TAN subpopulations and NETs concentration. Then, the correlation between ascitic NETs levels and clinical features were analyzed, and ROC curves were generated to evaluate the diagnostic value of NETs. For in vitro study, fresh neutrophils were employed to explore the underlying mechanism of TAN polarization and NETs formation using RNAseq analysis.
RESULTS: Significantly increased pro-tumor PD-L1+ TANs and higher lactate levels were measured in HCC ascites. RNAseq data showed that lactate regulated genes expression involving PD-L1 expression and NETs formation, suggesting that ascitic lactate might be responsible for tumor progression in TME. Then, NETs-related markers including calprotectin, dsDNA, CitH3, MPO and MPO-DNA were found dramatically elevated in malignant ascites. Next, correlation analysis revealed that ascitic NETs levels positively correlated with LDH, a classic ascitic biochemical indicator. Furthermore, we identified the diagnostic values of NETs in discriminating malignant ascites from benign ascites.
CONCLUSIONS: Our findings highlighted that elevated ascitic NETs served as a biomarker in HCC patients with malignant ascites, which provided useful insights for both clinical and basic research for malignant ascites diagnosis and management.
The presence of comorbidities among individuals with disabilities worsens their already complex health and social circumstances. This study aims to explore prevalence and patterns of morbidities among persons with disabilities in Bangladesh and identify associated socio-demographic factors. Data from 4270 persons with disability was analysed extracted from the 2021 Bangladesh National Household Survey on Persons with Disability. Outcome variable considered was the occurrence of morbidity among persons with disabilities. Explanatory variables encompassed factors at the individual, household, and community levels. Adjusted and unadjusted multilevel mixed-effects logistic regression model was used to explore association of outcome variable with explanatory variables. We found that approximately half of individuals with disabilities experienced one or more morbidities, with chronic conditions being the most prevalent (44%). Around 42% of total persons with disability were unable to work. Specifically, hypertension (18.3%), diabetes (9.1%), and heart problems (17.1%) were prevalent chronic conditions. The likelihood of experiencing comorbidity was found to be higher among females (aOR 1.3, 95% CI 1.1, 1.7), increase year of education (aOR, 1.1, 95% CI 1.0-1.2), and those from wealthier households (aOR 1.6, 95% CI 1.2, 2.2). This underscores the need for targeted policies and interventions addressing their distinct healthcare needs.
The invention discloses a kind of methods for extracting separation blue or green money willow flavones, include the following steps：A. blue or green money willow is washed with clear water, 40-50 DEG C of drying drying, sample is crushed through pulverizer, crosses 40 meshes；B. acidolysis；C. microbial fermentation is degraded；D. complex enzyme hydrolysis:E. acetone extract；F. crude flavonoid powder purifies：With activated carbon purification flavones.For the present invention in the extraction process of blue or green money willow flavones, the method for using first step microbial fermentation first falls the cell wall degradation of blue or green money willow, while removing a part of impurity etc., such as polysaccharide etc. using the effect of microorganism.Then flavones is sufficiently released with enzymatic hydrolysis again.Non-pollutant discharge in entire technical process of the invention, is suitable for being mass produced, and is beneficial to the development and utilization of blue or green money willow resource.Simple with the step, at low cost, strong operability, the high advantage of yield is easy to industrialized production.
In a pharmacokinetic study in patients with moderate hepatic impairment (Child-Pugh B) associated with significant liver tumor burden, 10 out of 15 patients died on treatment or within 30 days of the last TARCEVA dose. One patient died from hepatorenal syndrome, 1 patient died from rapidly progressing liver failure and the remaining 8 patients died from progressive disease. Six out of the 10 patients who died had baseline total bilirubin > 3 x ULN suggesting severe hepatic impairment. Treatment with TARCEVA should be used with extra caution in patients with total bilirubin > 3 x ULN. Patients with hepatic impairment (total bilirubin > ULN or Child-Pugh A, B and C) should be closely monitored during therapy with TARCEVA. TARCEVA dosing should be interrupted or discontinued if changes in liver function are severe such as doubling of total bilirubin and/or tripling of transaminases in the setting of pretreatment values outside normal range [see Clinical Pharmacology (12.3) and Dosage and Administration (2.3 )].
Provided is a multiagent-type hair treatment agent comprising a first composition that contains a component (A) and a component (B), and a second composition that contains a component (C), wherein the mass ratio (H)/(C) of a component (H) to the component (C) in the second composition is less than 1. Also provided is a hair treatment method comprising a step (i) in which the first composition is applied to hair and the hair is rinsed, and a step (ii) in which the second composition is then applied to the hair. Component (A): Carboxylic acid having an inorganic value of 230-450, and an organic value of 50-250, or a salt of the carboxylic acid. Component (B): Anionic surfactant. Component (C): Aromatic sulphonic acid having a molecular weight of 300 or less, or a salt thereof. Component (H): Cationic surfactant.
Aldesleukin, a human recombinant interleukin-2 product, is a highly purified protein with a molecular weight of approximately 15,300 daltons. The chemical name is des-alanyl-1, serine-125 human interleukin-2. Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) aldesleukin is not glycosylated because it is derived from E. coli ; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125; this was accomplished by site specific manipulation during the genetic engineering procedure; and d) the aggregation state of aldesleukin is likely to be different from that of native interleukin-2. The manufacturing process for aldesleukin involves fermentation in a defined medium containing tetracycline hydrochloride. The presence of the antibiotic is not detectable in the final product. 

The in vitro biological activities of the native nonrecombinant molecule have been reproduced with aldesleukin.1,2

Proleukin (aldesleukin) for injection is a sterile, preservative-free white to off-white, lyophilized powder, which has a cake-like appearance, supplied in single-dose vials for intravenous administration after reconstitution. When reconstituted with 1.2 mL Sterile Water for Injection, USP, each mL contains 18 million International Units (1.1 mg) aldesleukin, mannitol (50 mg), sodium dodecyl sulfate (0.19 mg), buffered with disodium hydrogen phosphate dihydrate (1.12 mg) and sodium dihydrogen phosphate dihydrate (0.19 mg) to a pH of 7.5 (range 7.2 to 7.8). 

Proleukin biological potency is determined by a lymphocyte proliferation bioassay and is expressed in International Units as established by the World Health Organization 1st International Standard for Interleukin-2 (human). The relationship between potency and protein mass is as follows:

18 million International Units Proleukin = 1.1 mg protein
A method of preparing a collagen sponge comprises mixing air into a collagen gel, so as to obtain collagen foam which is dried. From the dried product thereby obtained, collagen sponge is obtained byisolating parts of sponge with a chamber diameter of more than 0.75 mm and less than 4 mm, or parts with an average chamber diagonal dimensions of 3 mm. The collagen sponge comprises fibrin glue, e.g. a combination of fibrinogen, thrombin and aprotinin. A device for extracting a part of collagen foam and for degenerating another part of the collagen foam to a collagen gel is disclosed. An elongated collagen sponge having through-going hole or bore and a flexible wall may be used for re-establishing walls in a mammalian gastrointestinal tunnel or trachea system.
NEW MATERIAL:The 1(or 2 or 3)-formylpropoxycyclohexane of formula I (formyl group is bonded to the 1, 2 or 3 position). USE:Useful as a component of perfumery composition. It has fruity and aldehydic perfume and strong lasting fragrance. It can be used widely to the product necessitating the fragrance, e.g. perfumery, soap, shampoo, hair rinse, detergent, toiletry spray, aromatic agent, etc. PREPARATION:The compound of formula I can be prepared by reacting cyclohexal with allyl bromide, and reacting the resultant compound of formula II with carbon monoxide and hydrogen in the presence of rhodium catalyst and a tertiary phosphine at 0-170 deg.C, preferably 80-130 deg.C, keeping the partial pressure ration (CO/H2) to 0.5-2.0.
OBJECTIVE: To explore the independent risk factors for poor prognosis in patients with gastric cancer after resection and analyze the clinical application value of (connect-introduce-communicate-ask-respond-exit) CICARE communication mode combined with detailed nursing for such patients.
METHODS: 96 patients who underwent gastric cancer resection in our hospital from January 2019 to October 2019 were analyzed. They were divided into the good prognosis and poor prognosis group according to the postoperative adverse prognosis. The factors related to poor prognosis were analyzed by univariate and multivariate analysis. Another 106 patients who underwent gastric cancer resection from January 2020 to October 2021 were randomly divided into study and control group, with 53 patients in each group. The control group received routine nursing, and study group received CICARE communication mode combined with detailed nursing. Adverse mood changes were compared between the two groups before and after nursing. The changes of pain before surgery and 6 and 12 h after surgery were compared between the two groups as well as nursing satisfaction rate.
RESULTS: Univariate and multivariate results showed that body mass index (BMI) ≥ 28.00 kg/m2, length of hospital stay≥10 d, and preoperative complications≥2 were independent risk factors for poor prognosis after gastric cancer resection (P < .05). Compared with the control group, the incidence of postoperative adverse reactions in the study group was significantly reduced (P < .05). The bad mood of the two groups was alleviated compared with that before nursing, but the study group was significantly better than control (P < .05). The pain degree in both groups decreased with time, the study group was significantly lower than that in control (P < .05). Nursing satisfaction of the study group was significantly higher than that of control (P < .05).
CONCLUSION: BMI ≥ 28.00 kg/m2, length of hospital stay≥10 d, and preoperative complications ≥ 2 types can cause postoperative adverse reactions in patients with gastric cancer resection. CICARE detailed nursing based on the above risk factors can effectively reduce postoperative complications and relieve postoperative pain and adverse emotions of patients, which has high clinical application value.
PURPOSE:An ovulatory agent comprising an oil-soluble fraction of the whole grain or part of seed of Coix lacryma-job L. var. ma-yuen (Roman) Staph) as an active ingredient. CONSTITUTION:An oil-soluble fraction of the whole grain or part of seed of Coix lacryma-job L. var. ma-yuen (Roman) Staph) is extracted with n-hexane, ethyl acetate, etc., as an exracting solvent, to give an active ingredient as an ovulatory agent. The agent is optionally blended with an auxiliary component (e.g., excipient, compouding agent, diluent, etc.) for pharmaceutical manufacturing. An oral or parenteral drug such as powder, fine granule, tablet, capsule, syrup, injection, etc., may be cited as the dosage form. It promotes natural ovulating without side effects, keeps corpus luteum formation and has corpus luteum number increasing action.